American Journal of Medical Case Reports
ISSN (Print): 2374-2151 ISSN (Online): 2374-216X Website: Editor-in-chief: Samy, I. McFarlane
Open Access
Journal Browser
American Journal of Medical Case Reports. 2015, 3(5), 133-136
DOI: 10.12691/ajmcr-3-5-4
Open AccessCase Report

Late Onset Ornithine Transcarbamylase Deficiency Accompanying Severe HyperammonemiaAfter Cesarean Section: Case Report

Birsen Dogu1, , Nezir Yılmaz2, Sabriye Ozcekic2 and Hafize Oksuz2

1Marash Life Hospital, Kahramanmaras, Turkey

2Kahramanmaras Sutcu Imam University Medical School Department of Anesthesiology and Reanimation Kahramanmaras, Turkey

Pub. Date: April 16, 2015

Cite this paper:
Birsen Dogu, Nezir Yılmaz, Sabriye Ozcekic and Hafize Oksuz. Late Onset Ornithine Transcarbamylase Deficiency Accompanying Severe HyperammonemiaAfter Cesarean Section: Case Report. American Journal of Medical Case Reports. 2015; 3(5):133-136. doi: 10.12691/ajmcr-3-5-4


Hyperammonemia is one of the common complications of porto-systemic shunt or liver failure. In patients without liver failure or porto-systemic shunt, hyperammonemia can be caused by urea cycle disorders. Nitrogen excretion pathway or enzyme deficiency disorder can result in any hyperammonemia, coma, or death that may cause severe clinical encephalopathy presenting with neurological symptoms. The most common cause of genetic disorders in the urea cycle is ornithine carbamoyltransferase deficiency. In this article, 28-year-old female patient who had late-onset ornithine carbamoyltransferase deficiency with severe acute hyperammonemia resulting coma and death after cesarian section is described. In addition, treatment of hyperammonemia including sodium benzoate, arginine, and hemodialysis were discussed.

ornithine carbamoyltransferase deficiency urea cycle disorders hyperammonemia hemodialysis

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit


[1]  Brusilow SW, Maestri NE. “Urea cycle disorders: diagnosis, pathophysiology, and therapy”. Adv Pediatr ; 43. 127-70. 1996.
[2]  B.C. Lanpher, A. Gropman, K. A. Chapman, U. Lichter-Konecki,Urea CycleDisorders Consortium, andM. L. Summar, “Urea cycle disorders overview,” in GeneReviews [Internet], R.A.Pagon, T. D. Bird, C. R. Dolan, K. Stephens, and M. P. Adam, Eds., University of Washington, Seattle, Seattle, Wash, USA, 1993-2003.
[3]  Applegarth DA, Toone JR, Lowry RB. Incidence of inborn errors of metabolism in British Columbia, 1969-1996. Pediatrics 2000; 105: e10.
[4]  Kang ES, Snodgrass PJ, Gerald PS. “Ornithine transcarbamylase deficiency in the newborn infant”. J Pediatr. 82(4): 642-9, Apr.1973.
[5]  McCullough BA, Yudkoff M, Batshaw ML, Wilson JM, Raper SE, Tuchman M. “Genotype spectrum of ornithine transcarbamylase deficiency: correlation with the clinical and biochemical phenotype”. Am J Med Genet. 93(4). 313-9. Aug.2000.
[6]  Tuchman M, McCullough BA, Yudkoff M. “The molecular basis of ornithine transcarbamylase deficiency”. Eur J Pediatr. 159(Suppl 3). S196-8. Dec.2000.
[7]  Tuchman M, Morizono H, Rajagopal BS, Plante RJ, Allewell NM. “The biochemical and molecular spectrum of ornithine transcarbamylase deficiency”. J Inherit Metab Dis. 21(Suppl 1): 40-58. 1998
[8]  Gordon N. “Ornithine transcarbamylase deficiency: a urea cycle defect” Eur J Paediatr Neurol. 7(3). 115-21. 2003.
[9]  Ellaway CJ, Bennetts B, Tuck RR, Wilcken B. “Clumsiness, confusion,coma, and valproate”. Lancet. 353(9162). 1408. Apr24.1999.
[10]  Choi D.E, Lee K.W, Shin Y.T, and Na KR, “Hyperammonemia in a patient with late-onset ornithine carbamoyltransferase deficiency,”Journal of Korean Medical Science. 27(5). 556-9. May.2012.
[11]  Diaz G.A, Krivitzky L.S, Mokhtarani M. et al., “Ammonia control and neurocognitive outcome among urea cycle disorder patients treated with glycerol phenylbutyrate,” Hepatology. 57(6), 2171-9. Jun.2013.
[12]  Maillot F and Crenn P. “Urea cycle disorders in adult patients,”Revue Neurologique, 163(10). 897-903. Oct.2007.
[13]  Magoulas PL and El-Hattab AW, “Systemic primary carnitine deficiency: an overview of clinical manifestations, diagnosis, and management,” Orphanet Journal of Rare Diseases. 7. 68. Sep 18.2012.
[14]  Mock CM and Schwetschenau KH, “Levocarnitine for valproic-acid-induced hyperammonemic encephalopathy,” Am J Health Syst Pharm., 69(1).35-9. Jan1.2012.
[15]  Mathias RS, Kostiner D, Packman S. “Hyperammonemia in urea cycle disorders: role of the nephrologist.” Am J Kidney Dis. 37(5). 1069-80. May. 2001.
[16]  Wiegand C, Thompson T, Bock GH, Mathis RK, Kjellstrand CM, Mauer SM. “The management of life-threatening hyperammonemia: a comparison of several therapeutic modalities”. J Pediatr. 96(1). 142-4. Jan.1980.